Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2019, specifically dated August 6, 2019. The filing serves to incorporate a press release regarding the operational status of the Company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change reported is the successful manufacturing of a supply of Namodenoson. This supply is now ready for use in the treatment of advanced liver cancer patients under a compassionate use program at the Rabin Medical Center in Israel.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference but does not detail specific guidance, outlook, or risk factors within the body of this Form 6-K. The focus is strictly on the availability of the drug for compassionate use.
Investor Verification Checklist
- Verify the specific terms and patient eligibility criteria for the compassionate use program at Rabin Medical Center.
- Review the full text of the attached press release (Exhibit 99.1) for detailed forward-looking statements and associated risks.
- Confirm the timeline for patient enrollment and the expected duration of the compassionate use supply.
- Check subsequent filings for any updates on the clinical progress or regulatory status of Namodenoson.